Table 1.
Baseline characteristics and univariate analysis of risk factors for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis. IQR, interquartile ranges.
Parameter | The serious bleeding group | The non-serious bleeding group | p value |
---|---|---|---|
(n = 14) | (n = 23) | ||
Age (years, mean (SD)) | 40.6 (4.7) | 40.8 (4.3) | 0.845 |
BMI (kg/m2, mean (SD)) | 20.7 (3.1) | 21.5 (4.4) | 0.583 |
Nulliparous (n (%; 95% CI)) | 7 (50%) | 12 (52%) | 1.000 |
Severe dysmenorrhea | 14 (100%) | 20 (87%) | 0.275 |
Prior therapy | 6 (43%) | 10 (43%) | 1.000 |
Previous cesarean delivery | 0 (0%) | 5 (21.7%) | 0.135 |
Previous endometrial curettage | 5 (36%) | 11 (48%) | 0.471 |
Presence of hypermenorrhea | 8 (57%) | 13 (57%) | 0.970 |
Minimum hemoglobin level before DNG treatment (g/dl, mean(SD)) | 11.2 (1.3) | 12.0 (1.2) | 0.074 |
Minimum hemoglobin level after or during DNG treatment (g/dl, mean(SD)) | 8.3 (1.1) | 11.8 (1.2) | 0.000 |
Duration of treatment with DNG (month, IQR, range) | 3.5 (IQR, 6.8; range, 2.0–24.0) | 15.0 (IQR, 33.0; range, 3.0–96.0) | 0.001 |
The presence of endometriotic cyst | 4 (29%) | 14 (61%) | 0.091 |
The presence of leiomyoma | 4 (29%) | 11 (48%) | 0.314 |
Median maximum diameter of adenomyosis associated lesion (mm, IQR, range) | 37.5 (IQR, 13.4; range, 22.9–76.3) | 33.0 (IQR, 26.4; range, 16.0–72.1) | 0.056 |
Median maximum distance between uppermost part of uterine cavity and internal os (mm, IQR, range) | 87.6 (IQR, 40.5; range, 46.0–124.6) | 73.0 (IQR, 31.4; range, 55.0–132.3) | 0.313 |
Median maximum diameter of myometrial wall thickness (mm, IQR, range) | 45.3 (IQR, 12.9; range, 30.4–76.3) | 41.8 (IQR, 32.1; range, 21.0–72.1) | 0.090 |
Subtype I Adenomyosis | 8 (57%) | 4 (17%) | 0.027 |